TPST

Business Context and Reporting Period

Company: Tempest Therapeutics, Inc. (TPST)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Tempest is a clinical-stage biotechnology company focused on developing targeted and immune-mediated oncology therapies. The company has no approved products and generates no revenue. Its primary assets are two clinical-stage product candidates: Amezalpat (PPARα antagonist for hepatocellular carcinoma) and TPST-1495 (dual EP2/EP4 antagonist for Familial Adenomatous Polyposis).

Key Financial Metrics

Note: The company reported no revenue for either period. The filing text does not provide specific gross margin or operating margin percentages due to the absence of revenue.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately 42% (from $29.5 million to $41.8 million) driven primarily by higher research and development (R&D) expenses.
• R&D Expenses: Increased by 63% to $28.5 million. This was largely due to costs associated with preparing for the pivotal Phase 3 trial of amezalpat and increased contract research services.
• General and Administrative (G&A): Increased by 16% to $13.6 million, attributed to higher stock-based compensation and legal/consulting fees.
• Cash Position: Cash and cash equivalents decreased by approximately $9.0 million year-over-year, reflecting a net cash outflow from operating activities of $33.0 million, partially offset by $24.5 million in financing proceeds.
• Debt Repayment: The company made principal payments of $4.4 million on its Oxford Finance loan during 2024.

Guidance, Outlook, and Risks

Outlook and Milestones

• Amezalpat: Received FDA "Study May Proceed" letter in November 2024 for a pivotal Phase 3 trial in first-line hepatocellular carcinoma (HCC). In early 2025, the FDA granted Orphan Drug Designation and Fast Track Designation. The company is actively preparing to initiate the Phase 3 study.
• TPST-1495: Received FDA "Study May Proceed" letter in March 2025 for an NCI-funded Phase 2 trial in Familial Adenomatous Polyposis (FAP), expected to begin in 2025.
• Capital Needs: Management states that existing cash ($30.3 million as of Dec 31, 2024) is sufficient to fund operations for at least 12 months. However, significant additional capital is required to fund the Phase 3 trial for amezalpat.

Risks and Contingencies

• Liquidity Risk: The company has a history of operating losses and an accumulated deficit of $207.1 million. Failure to secure additional financing could force the company to delay, reduce, or terminate development programs.
• Debt Covenants: The company has a term loan with Oxford Finance LLC secured by a lien on all assets, including intellectual property. The loan matures on August 1, 2025. Default could lead to acceleration of repayment and foreclosure on assets.
• Regulatory Risk: Success depends on obtaining regulatory approval for product candidates, which is uncertain. Clinical trial results may not support approval, or the FDA may require additional studies.
• Stockholder Rights Plan: The company has an active "poison pill" rights plan amended in late 2024, which may discourage change-of-control transactions.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $30.3 million cash balance against the projected costs of the upcoming Phase 3 amezalpat trial.
• Debt Maturity: Confirm the status of the Oxford Finance loan maturing August 1, 2025, and the company's plan for refinancing or repayment.
• ATM Program Capacity: Review the remaining capacity under the At-The-Market (ATM) offering program (approx. $13.4 million as of March 2025) and constraints due to public float limits.
• Clinical Trial Initiation: Monitor the actual start date of the pivotal Phase 3 amezalpat trial and the NCI-funded Phase 2 TPST-1495 trial.
• Regulatory Designations: Track the utilization of Fast Track and Orphan Drug Designations for potential accelerated approval pathways.